Table 3 Concluding remarks and future directions
Expression observed in t(12;21) ALLs | Major expected cellular effects | Comments | Future directions |
|---|---|---|---|
Over expression of CNN2 | Mediates cellular growth arrest | In favor of good prognosis associated to t(12;21) | Is CNN2 a marker of good prognosis? It has to be confirmed with a largest group of patients |
Over expression of MAT-2β | Favors the cell proliferation with anti-apoptotic effect | Would be a marker of cancer aggressiveness | Would be explore as a target of chemotherapy |
Over expression of hnRNPA2 | Favors the cell proliferation | Would be a marker of cancer aggressiveness | Would be explore as a target of chemotherapy |
Over expression of PITPβ | Slow down the cell proliferation | Is it a marker of good prognosis? | Exploration of the balance PITPα/β |
Under expression of BUB3 | Avoid slippage of mitosis | Over expression in non t(12;21) could lead to hypo/hyperpolyploid cells | Mitoses analysis |
Under expression of hnRNPE2 | Favors apoptosis | In favor of good prognosis associated to t(12;21) | Exploration of the balance between hnRNPE2, PSMB2 and PSMB6 and/or checkup the apoptosis pathways |
Over expression of PSMB2 | Favors apoptosis | ||
Under expression of PSMB6 | Hinders apoptosis | In favor of leukogenesis | |
Under expression of CK2α | Slow down the proliferation by apoptotic effect | In favor of good prognosis associated to t(12;21) | Both expressions in combination with Ikaros (Ikzf1) phosphorylation and degradation ought to be clarified precisely |
Over expression of HSPC263(OTUB1) | Favors deubiquitination | Does it prevent Ikaros (Ikzf1) degradation? | |
Under expression of metabolism pathway proteins (i.e., CDSα; CECR5; PDH; IVAD; IDH; Electron transfer flavoprotein) | Sign the level of energetic consumption | In favor of good prognosis associated to t(12;21) | Checkup lymphoblasts metabolism pathway: High amount would be in accord with cancer aggressiveness |